Latest Blog

Spotlight on Veeva: 10 Questions with Kimberly Paris, Global Vice President of Quality Assurance

Quotient Sciences to Present on Tufts CSDD Study of Translational Pharmaceutics at Biotech Showcase 2020 in San Francisco

18th December 2019

QUOTIENT SCIENCES TO PRESENT ON TUFTS CSDD STUDY OF TRANSLATIONAL PHARMACEUTICS® AT BIOTECH SHOWCASE™ 2020 IN SAN FRANCISCO

Tufts Center for the Study of Drug Development Demonstrates Multi-Million Dollar Benefits of Quotient Sciences’ Translational Pharmaceutics Platform

San Francisco, CA/December 2019- Quotient Sciences, today announced plans to present on the latest Tufts CSDD White Paper assessing the timeline reductions and multi-million dollar cost savings of Translational Pharmaceutics® at Biotech Showcase 2020™, to be held January 13-15, during the most important week in healthcare at the Hilton San Francisco Union Square.

Peter Scholes, Quotient Sciences’ Chief Scientific Officer, will be presenting the talk entitled: Analysis from the Tufts CSDD study to Assess the Financial Benefits from Translational Pharmaceutics®:  A Platform for Accelerating Product Development

Date: January 14, 2020
Time: 4:45 (PST)
Room: Franciscan C (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)

Quotient Sciences is an innovative drug development and manufacturing organization supporting clients across the full development cycle from candidate selection through to commercial supply.  Their unique Translational Pharmaceutics® platform, accelerates development by integrating formulation development, real-time manufacturing and clinical testing.  At Biotech Showcase, Dr. Scholes will present a summary of the recent Tufts CSDD study, comparing Quotient’s Translational Pharmaceutics® platform to traditional development programs, which concluded that Translational Pharmaceutics®, on average, reduced development timelines by more than 12 months and delivers financial gains of more than $200 million per approved new drug. Dr. Scholes’ presentation will also describe client case studies of Translational Pharmaceutics programs, demonstrating how the platform can either be applied to accelerate molecules from first-in-human (FIH) to proof-of-concept (POC), or to develop and optimize clinical formulations for downstream patient trials and commercialization.

“Biotech Showcase is the perfect venue for Quotient Sciences to present on the recent Tufts CSDD findings on our Translational Pharmaceutics platform. Biotech companies and the biotech community as a whole is a major beneficiary of the time savings and financial benefits that Translational Pharmaceutics offers, relative to traditional drug development paradigms,” said Dr. Scholes. “At Quotient, we’re focused on accelerating the development of new medicines for patients by helping our customers improve their R&D productivity.”

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.

“We are delighted that Quotient Sciences will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”

To schedule a one-to-one partnering meeting with Peter Scholes at the event visit: https://informaconnect.com/biotech-showcase/partnering/

ABOUT BIOTECH SHOWCASE

Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its 12th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

ABOUT QUOTIENT SCIENCES

Quotient Sciences, a global pharmaceutical development, clinical and commercial manufacturing organization, delivers innovative, customized solutions for pharmaceutical and biotech customers through both individual and integrated services. Quotient’s Translational Pharmaceutics® platform integrates formulation development, real-time adaptive GMP manufacturing, and clinical research for the continuous improvement of drug development programs — and is proven to accelerate timelines and reduce cost.  For more information visit www.quotientsciences.com.

Contacts

Matthew Paterson
VP, Strategic Marketing
Quotient Sciences
matthew.paterson@quotientsciences.com

Quotient Sciences
3080 McCann Farm Dr., Garnet Valley, PA 19060
www.QuotientSciences.com
1-800-769 3518

Follow Quotient Sciences on Twitter at @Quotient_Sci and on LinkedIn at @Quotient_Sciences and Biotech Showcase at @EBDGroup and @Demy_Colton and tag your posts with #BiotechShowcase.

News

Read related news

Ask us a question

We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.